Item 8.01 Other Events.
On February 27, 2014, Peregrine Pharmaceuticals, Inc. (the "Company") announced
that the underwriters of its underwritten public offering of its 10.50% Series E
Convertible Preferred Stock (the "Series E Preferred Stock") have partially
exercised their option to cover overallotments and have purchased an additional
75,000 shares of Series E Preferred Stock from the Company at the public
offering price of $25.00 per share. A copy of the press release is filed hereto
as Exhibit 99.1.
The legal opinion of K&L Gates LLP relating to the shares of Series E Preferred
Stock in connection with this option exercise is filed as Exhibit 5.1 to this
Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following material is filed as an exhibit to this Current
Report on Form 8-K:
5.1 Opinion of K&L Gates LLP.
23.1 Consent of K&L Gates LLP (included in the opinion filed as
99.1 Press Release issued February 27, 2014.